GENE ONLINE|News &
Opinion
Blog

2021-05-14| In-DepthTechnology

ASGCT21 Highlights: Present Trends and Future Directions of Gene and Cell Therapies in Immuno-Oncology

by Daniel Ojeda
Share To
During the virtual ASGCT meeting, experts reflected on the current trends and future directions of gene and cell therapies in immuno-oncology.

Engineering T Cells to Better Recognize Cancer Cells
Current immune checkpoint therapies try to release the breaks of the T cells to fight cancer. Most of these therapies target either CTLA-4, which prevents T cell activation at the lymph nodes or PD-1/PD-L1, which downregulates T cell activity in the tumor microenvironment.

GO Prime with only $1.49 now

LATEST
Lupin Secures US FDA Tentative Approval for Oxcarbazepine ER Tablets Manufactured in Nagpur
2025-06-18
Investor Trust and Market Timing Shape the New IPO Playbook
2025-06-18
Global Pharmaceutical Sector Records $6.96 Billion in May 2025 Deal Activity with Three Major Agreements Driving 59 Percent of M&A Value
2025-06-18
Eli Lilly Acquires SiteOne Therapeutics to Develop Non-Opioid Pain Treatment STC-004
2025-06-18
New Device Promises to Streamline CAR T-Cell Therapy Production for Earlier Cancer Treatment
2025-06-18
Roche Reports Near-Complete Suppression of Disability Progression in RMS Patients Over Two Years with BTK Inhibitor
2025-06-18
Technological Advancements Reduce R&D Costs and Propel Growth of Cell and Gene Therapies in Biopharmaceutical Sector
2025-06-18
EVENT
2025-06-16
US BIO International Convention
Boston, U.S.A.
Scroll to Top